9 research outputs found
U.S. Inhibitor Pilot Project: Study Design And Methods Validation
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106090/1/jth01876.pd
Prophylaxis escalation in severe von Willebrand disease: A prospective study from the von Willebrand Disease Prophylaxis Network
Background: Treatment of mucosal bleeding (epistaxis, gastrointestinal bleeding, and menorrhagia) and joint bleeding remains problematic in clinically severe von Willebrand disease (VWD). Patients are often unresponsive to treatment (e.g. desmopressin or antifibrinolytic therapy) and may require von Willebrand factor (VWF) replacement therapy. There are little data on the use of prophylaxis in VWD, and none have been applied in a prospective, treatment escalation design. Objective: Evaluate the effect of escalating dose prophylaxis in severe VWD. Methods: Patients eligible for enrollment in this prospective study included those with type 1 VWD with VW factor activity-ristocetin cofactor ratio ≤ 20% and unresponsive to desmopressin, patients with type 2 VWD not responsive to desmopressin and all subjects with type 2B and type 3 VWD. Entry criteria were strictly defined, as were therapy escalation parameters and clinical data collection. Results: Eleven subjects completed the study. Six had type 2A, and five had type 3 VWD. Six patients presented with epistaxis, three with GI bleeding, and two with joint bleeding. Seven had dose escalation above the first level. Among the 10 subjects with evaluable bleeding log data, use of prophylaxis decreased the median annualized bleeding rate from 25 to 6.1 (95% confidence interval of the rate difference: -51.6 to -1.7), and the median annualized bleeding rate was even lower (4.0; 95% confidence interval: -57.5 to -5.3) when the subjects reached their final dosing level. Conclusion: This is the first prospective study to demonstrate that prophylaxis with VW factor concentrates is highly effective in reducing mucosal and joint bleeding rates in clinically severe VWD
Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, and type 1
VWD is the most common VWD variant. Despite its frequency, diagnosis of type 1 VWD
remains the subject of much debate. In order to study the spectrum of type 1 VWD in the United
States, the Zimmerman Program enrolled 482 subjects with a previous diagnosis of type 1 VWD
without stringent laboratory diagnostic criteria. VWF laboratory testing and full length VWF
gene sequencing were performed for all index cases and healthy control subjects in a central
laboratory. Bleeding phenotype was characterized using the ISTH Bleeding Assessment Tool.
At study entry, 64% of subjects had VWF:Ag or VWF:RCo below the lower limit of normal,
while 36% had normal VWF levels. VWF sequence variations were most frequent in subjects
with VWF:Ag < 30 IU/dL (82%) while subjects with type 1 VWD and VWF:Ag ≥ 30 IU/dL had
an intermediate frequency of variants (44%). Subjects whose VWF testing was normal at study
entry had a similar rate of sequence variations as the healthy controls at 14% of subjects. All
subjects with severe type 1 VWD and VWF:Ag ≤ 5 IU/dL had an abnormal bleeding score, but
otherwise bleeding score did not correlate with VWF:Ag level. Subjects with a historical
diagnosis of type 1 VWD had similar rates of abnormal bleeding scores compared to subjects
with low VWF levels at study entry. Type 1 VWD in the United States is highly variable, and
bleeding symptoms are frequent in this population